Published in Front Cell Dev Biol on February 20, 2015
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res (2010) 11.42
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet (1964) 9.32
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (1984) 8.80
A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol (1965) 8.64
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer (2005) 4.66
Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer (1977) 4.53
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat Immunol (2010) 2.80
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med (1996) 2.75
CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev (2006) 2.39
BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 2.25
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell (2010) 1.95
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood (2008) 1.85
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer (1978) 1.77
Characterization of a leukemic cell line of the pre-B phenotype. Int J Cancer (1979) 1.76
CKIα ablation highlights a critical role for p53 in invasiveness control. Nature (2011) 1.72
Identification of inhibitory autophosphorylation sites in casein kinase I epsilon. J Biol Chem (1999) 1.67
Casein kinase 1: Complexity in the family. Int J Biochem Cell Biol (2010) 1.63
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med (2014) 1.62
Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem (2000) 1.59
Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol (1981) 1.50
p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene (1997) 1.46
IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene (2000) 1.36
The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. Front Oncol (2014) 1.33
Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood (1986) 1.29
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell (2014) 1.28
The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J (2012) 1.26
Regulation of casein kinase I epsilon and casein kinase I delta by an in vivo futile phosphorylation cycle. J Biol Chem (1998) 1.23
Catalytic activity of protein kinase CK1 delta (casein kinase 1delta) is essential for its normal subcellular localization. Exp Cell Res (2001) 1.21
The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie (2005) 1.20
U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma. Cytogenet Genome Res (2008) 1.18
Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol (2009) 1.18
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res (2007) 1.18
Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res (1986) 1.17
IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation. Oncogene (2011) 1.15
Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev (2010) 1.09
A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia (1991) 1.08
Morphologic, immunologic, enzymehistochemical and chromosomal analysis of a cell line derived from Hodgkin's disease. Evidence for a B-cell origin of Sternberg-Reed cells. Cancer (1985) 1.04
Inhibition of casein kinase I delta alters mitotic spindle formation and induces apoptosis in trophoblast cells. Oncogene (2005) 0.99
Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Mol Cancer (2014) 0.98
Phosphorylation of CK1delta: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo. Biochem J (2007) 0.98
B-cell non-Hodgkin's lymphoma cell line (Karpas 1106) with complex translocation involving 18q21.3 but lacking BCL2 rearrangement and expression. Blood (1994) 0.96
Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. Apoptosis (2011) 0.90
Biochemical and cellular characteristics of the four splice variants of protein kinase CK1alpha from zebrafish (Danio rerio). J Cell Biochem (2002) 0.90
MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma. Int J Cancer (2001) 0.89
3D nuclear organization of telomeres in the Hodgkin cell lines U-HO1 and U-HO1-PTPN1: PTPN1 expression prevents the formation of very short telomeres including "t-stumps". BMC Cell Biol (2010) 0.88
Identification of four alternatively spliced isoforms of chicken casein kinase I alpha that are all expressed in diverse cell types. Gene (1998) 0.87
Casein kinase 1 and Wnt/β-catenin signaling. Curr Opin Cell Biol (2014) 0.86
CSNK1α1 mediates malignant plasma cell survival. Leukemia (2014) 0.85
Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. Int J Cancer (2007) 0.85
Casein kinase I delta (CKIdelta) is involved in lymphocyte physiology. Eur J Cell Biol (2003) 0.85
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. J Med Chem (2009) 0.83
Four casein kinase I isoforms are differentially partitioned between nucleus and cytoplasm. Exp Cell Res (2001) 0.83
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol (2014) 0.82
2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1δ/ε. Amino Acids (2012) 0.79
CK1δ kinase activity is modulated by Chk1-mediated phosphorylation. PLoS One (2013) 0.79
Microtubules depolymerization caused by the CK1 inhibitor IC261 may be not mediated by CK1 blockage. PLoS One (2014) 0.79
Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients. Int J Cancer (2014) 0.79
Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1δ and ε with nanomolar inhibitory activity on cancer cell proliferation. J Med Chem (2014) 0.76